Gastric emptying and satiety signaling
The gut-brain routes through which incretin signaling reduces food intake.
Beyond the pancreas, GLP-1 acts on two mechanisms that reduce food intake. It slows gastric emptying, so a meal leaves the stomach more gradually and fullness persists. And it acts on appetite-regulating centres in the brain — notably in the hypothalamus and hindbrain — reducing hunger and the drive to eat.
Together these enhance satiety and lower overall caloric intake, and they account for much of the weight change observed with incretin-based approaches. They also account for much of the gastrointestinal tolerability profile reported in trials: the same slowed emptying that promotes fullness produces nausea in a meaningful fraction of participants, particularly during dose escalation.
The gut-brain axis is central to why the incretin system turned out to be about more than glucose. It is a nutrient-sensing pathway with reach into energy balance — see Metabolic syndrome.
Related articles
- MetabolicGLP-1 receptor agonistsHow GLP-1 works, and why molecules mimicking it became central to metabolic research.
- MetabolicThe incretin effectThe observation that started incretin science: glucose taken by mouth triggers far more insulin than the same glucose given intravenously.
- MetabolicMetabolic syndromeThe cluster of findings — central adiposity, dysglycaemia, dyslipidaemia, raised blood pressure — that tend to travel together.
- MetabolicCardiovascular and renal findings in incretin researchWhy outcome trials — not surrogate markers — reshaped how incretin science is understood.
- MetabolicGIP and its receptorThe other incretin hormone — long overshadowed by GLP-1, now central to combination approaches.
- MetabolicDual GIP/GLP-1 receptor agonistsEngineering one molecule to engage two incretin receptors — and what head-to-head data showed.